| Symbol | KYMR |
|---|---|
| Name | KYMERA THERAPEUTICS, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Address | 200 ARSENAL YARDS BOULEVARD,SUITE 230, WATERTOWN, Massachusetts, 02472, United States |
| Telephone | +1 857 285-5300 |
| Fax | — |
| — | |
| Website | https://www.kymeratx.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001815442 |
| Description | Kymera Therapeutics Inc is a biotechnology company pioneering a transformative new approach to treating previously untreatable diseases. The company is advancing the field of targeted protein degradation, accessing the bodys innate protein recycling machinery to degrade dysregulated, disease-causing proteins. Kymeras Pegasus targeted protein degradation platform harnesses the bodys natural protein recycling machinery to degrade disease-causing proteins, with a focus on un-drugged nodes in validated pathways currently inaccessible with conventional therapeutics. It is accelerating drug discovery with an unmatched ability to target and degrade intractable proteins and advance new treatment options for patients. Additional info from NASDAQ: |
Jacobs Bruce N. 🟡 adjusted position in 0 shares (1 derivative) of Kymera Therapeutics, Inc. (KYMR) at $2.08 Transaction Date: May 18, 2026 | Filing ID: 229656
Read moreKymera Therapeutics Announces Presentations on KT-621, a First-In-Class, Oral STAT6 Degrader, at the Society for Investigative Dermatology and American Thoracic Society Congresses
Read moreNew Form SCHEDULE 13G/A - Kymera Therapeutics, Inc. <b>Filed:</b> 2026-05-15 <b>AccNo:</b> 0000902219-26-000204 <b>Size:</b> 15 KB
Read moreSHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Kymera Therapeutics, Inc. (NASDAQ: KYMR)
Read moreRidloff Elena 🟡 adjusted position in 3.0K shares (1 derivative) of Kymera Therapeutics, Inc. (KYMR) at $87.00 Transaction Date: May 11, 2026 | Filing ID: 217041
Read more📋 ELENA RIDLOFF (Director) plans to sell 3K shares of KYMERA THERAPEUTICS, INC. (at $86.08 each, total $258K) Filed: May 11, 2026 | ID: 004332
Read moreNew Form SCHEDULE 13G/A - Kymera Therapeutics, Inc. <b>Filed:</b> 2026-05-06 <b>AccNo:</b> 0000315066-26-001229 <b>Size:</b> 11 KB
Read moreKymera Therapeutics Presents New Preclinical IBD Data for KT-579, a First-in-Class, Oral IRF5 Degrader, at Digestive Disease Week
Read moreJeito Capital Bolsters Its Leadership Team With the Appointment of Elaine Caughey, MBA, as Partner, Business Development and Investor Relations, and Sarah Shackelton, MPA, as Partner, Talent
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT07412288 | First-in-human Study of Orally Administered KT-579 in Healthy Adult Participants | Phase1 | Healthy Participants | Recruiting | 2026-02-23 | 2026-12-01 | ClinicalTrials.gov |
| NCT07323654 | A Study of KT-621 Administered Orally to Adult Participants With Moderate to Se… | Phase2 | Eosinophilic Asthma | Recruiting | 2026-01-28 | 2027-12-01 | ClinicalTrials.gov |
| NCT07217015 | A Study of KT-621 Administered Orally to Participants With Moderate to Severe A… | Phase2 | Atopic Dermatitis | Recruiting | 2025-11-24 | 2028-06-01 | ClinicalTrials.gov |
| NCT06945458 | Safety, PK, PD, and Clinical Activity of Orally Administered KT-621 in Adult Pa… | Phase1 | Atopic Dermatitis | Completed | 2025-04-17 | 2025-11-10 | ClinicalTrials.gov |
| NCT06673667 | First-in-human Study of Orally Administered KT-621 in Healthy Adult Participants | Phase1 | Healthy Participants Study | Completed | 2024-10-22 | 2025-04-23 | ClinicalTrials.gov |
| NCT05775406 | Safety and Clinical Activity of KT-253 in Adult Patients with High Grade Myeloi… | Phase1 | Myeloid Malignancies | Completed | 2023-05-15 | 2024-12-18 | ClinicalTrials.gov |
| NCT05233033 | Safety, PK/PD, and Clinical Activity of KT-413 in Adult Patients with Relapsed … | Phase1 | Non Hodgkin Lymphoma | Completed | 2022-06-13 | 2023-07-28 | ClinicalTrials.gov |
| NCT05225584 | Safety, PK, PD, Clinical Activity of KT-333 in Adult Patients With Refractory L… | Phase1 | Non Hodgkin Lymphoma (NHL) | Completed | 2022-05-19 | 2025-03-03 | ClinicalTrials.gov |
| NCT04772885 | A Single and Multiple Ascending Dose Trial of KT-474 in Healthy Adult Volunteer… | Phase1 | Healthy Volunteer | Completed | 2021-02-23 | 2022-10-20 | ClinicalTrials.gov |
| NCT04440410 | Evaluation of Cutaneous and Circulating Inflammatory Biomarkers in Hidradenitis… | — | Hidradenitis Suppurativa | Completed | 2020-05-28 | 2021-03-24 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Placebo | Other | Phase PHASE2 | Atopic Dermatitis | RECRUITING | NCT07217015 |
| KT-621 | Other | Phase PHASE2 | Atopic Dermatitis | RECRUITING | NCT07217015 |
| Placebo | Other | Phase PHASE2 | Eosinophilic Asthma | RECRUITING | NCT07323654 |
| KT-621 | Other | Phase PHASE2 | Eosinophilic Asthma | RECRUITING | NCT07323654 |
| Placebo | Other | Phase PHASE2 | Atopic Dermatitis | RECRUITING | NCT07217015 |
| KT-621 | Other | Phase PHASE2 | Atopic Dermatitis | RECRUITING | NCT07217015 |
| Placebo | Other | Phase PHASE2 | Eosinophilic Asthma | RECRUITING | NCT07323654 |
| KT-621 | Other | Phase PHASE2 | Eosinophilic Asthma | RECRUITING | NCT07323654 |
| Placebo | Other | Phase PHASE2 | Atopic Dermatitis | RECRUITING | NCT07217015 |
| KT-621 | Other | Phase PHASE2 | Atopic Dermatitis | RECRUITING | NCT07217015 |
| Placebo | Other | Phase PHASE2 | Eosinophilic Asthma | RECRUITING | NCT07323654 |
| KT-621 | Other | Phase PHASE2 | Eosinophilic Asthma | RECRUITING | NCT07323654 |
| Placebo | Other | Phase PHASE2 | Atopic Dermatitis | RECRUITING | NCT07217015 |
| KT-621 | Other | Phase PHASE2 | Atopic Dermatitis | RECRUITING | NCT07217015 |
| Placebo | Other | Phase PHASE2 | Eosinophilic Asthma | RECRUITING | NCT07323654 |
| KT-621 | Other | Phase PHASE2 | Eosinophilic Asthma | RECRUITING | NCT07323654 |
| Placebo | Other | Phase PHASE2 | Atopic Dermatitis | RECRUITING | NCT07217015 |
| KT-621 | Other | Phase PHASE2 | Atopic Dermatitis | RECRUITING | NCT07217015 |
| Placebo | Other | Phase PHASE2 | Eosinophilic Asthma | RECRUITING | NCT07323654 |
| KT-621 | Other | Phase PHASE2 | Eosinophilic Asthma | RECRUITING | NCT07323654 |
| Placebo | Other | Phase PHASE2 | Atopic Dermatitis | RECRUITING | NCT07217015 |
| KT-621 | Other | Phase PHASE2 | Atopic Dermatitis | RECRUITING | NCT07217015 |
| Placebo | Other | Phase PHASE2 | Eosinophilic Asthma | RECRUITING | NCT07323654 |
| KT-621 | Other | Phase PHASE2 | Eosinophilic Asthma | RECRUITING | NCT07323654 |
| Placebo | Other | Phase PHASE2 | Atopic Dermatitis | RECRUITING | NCT07217015 |
| KT-621 | Other | Phase PHASE2 | Atopic Dermatitis | RECRUITING | NCT07217015 |
| Placebo | Other | Phase PHASE2 | Eosinophilic Asthma | RECRUITING | NCT07323654 |
| KT-621 | Other | Phase PHASE2 | Eosinophilic Asthma | RECRUITING | NCT07323654 |
| Placebo | Other | Phase PHASE2 | Atopic Dermatitis | RECRUITING | NCT07217015 |
| KT-621 | Other | Phase PHASE2 | Atopic Dermatitis | RECRUITING | NCT07217015 |
| Placebo | Other | Phase PHASE2 | Eosinophilic Asthma | RECRUITING | NCT07323654 |
| KT-621 | Other | Phase PHASE2 | Eosinophilic Asthma | RECRUITING | NCT07323654 |
| Placebo | Other | Phase PHASE2 | Atopic Dermatitis | RECRUITING | NCT07217015 |
| KT-621 | Other | Phase PHASE2 | Atopic Dermatitis | RECRUITING | NCT07217015 |
| Placebo | Other | Phase PHASE2 | Eosinophilic Asthma | RECRUITING | NCT07323654 |
| KT-621 | Other | Phase PHASE2 | Eosinophilic Asthma | RECRUITING | NCT07323654 |
| Placebo | Other | Phase PHASE2 | Eosinophilic Asthma | RECRUITING | NCT07323654 |
| KT-621 | Other | Phase PHASE2 | Eosinophilic Asthma | RECRUITING | NCT07323654 |
| Placebo | Other | Phase PHASE2 | Atopic Dermatitis | RECRUITING | NCT07217015 |
| KT-621 | Other | Phase PHASE2 | Atopic Dermatitis | RECRUITING | NCT07217015 |
| Placebo | Other | Phase PHASE2 | Eosinophilic Asthma | RECRUITING | NCT07323654 |
| KT-621 | Other | Phase PHASE2 | Eosinophilic Asthma | RECRUITING | NCT07323654 |
| Placebo | Other | Phase PHASE2 | Atopic Dermatitis | RECRUITING | NCT07217015 |
| KT-621 | Other | Phase PHASE2 | Atopic Dermatitis | RECRUITING | NCT07217015 |
| Placebo | Other | Phase PHASE2 | Eosinophilic Asthma | RECRUITING | NCT07323654 |
| KT-621 | Other | Phase PHASE2 | Eosinophilic Asthma | RECRUITING | NCT07323654 |
| Placebo | Other | Phase PHASE2 | Atopic Dermatitis | RECRUITING | NCT07217015 |
| KT-621 | Other | Phase PHASE2 | Atopic Dermatitis | RECRUITING | NCT07217015 |
| Placebo | Other | Phase PHASE2 | Eosinophilic Asthma | RECRUITING | NCT07323654 |
| KT-621 | Other | Phase PHASE2 | Eosinophilic Asthma | RECRUITING | NCT07323654 |
| KT-474 | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT04772885 |
| KT-474/Placebo | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT04772885 |
| KT-413 | Other | Phase PHASE1 | Non Hodgkin Lymphoma | COMPLETED | NCT05233033 |
| KT-253 | Other | Phase PHASE1 | Myeloid Malignancies | COMPLETED | NCT05775406 |
| KT-333 | Other | Phase PHASE1 | Non Hodgkin Lymphoma (NHL) | COMPLETED | NCT05225584 |
| Placebo | Other | Phase PHASE1 | Healthy Participants Study | COMPLETED | NCT06673667 |
| KT-621 | Other | Phase PHASE1 | Healthy Participants Study | COMPLETED | NCT06673667 |
| KT-621 | Other | Phase PHASE1 | Atopic Dermatitis | COMPLETED | NCT06945458 |
| Placebo | Other | Phase PHASE1 | Healthy Participants | RECRUITING | NCT07412288 |
| KT-579 | Other | Phase PHASE1 | Healthy Participants | RECRUITING | NCT07412288 |
| Placebo | Other | Phase PHASE2 | Eosinophilic Asthma | RECRUITING | NCT07323654 |
| KT-621 | Other | Phase PHASE2 | Eosinophilic Asthma | RECRUITING | NCT07323654 |
| Placebo | Other | Phase PHASE2 | Atopic Dermatitis | RECRUITING | NCT07217015 |
| KT-621 | Other | Phase PHASE2 | Atopic Dermatitis | RECRUITING | NCT07217015 |
| Placebo | Other | Phase PHASE2 | Atopic Dermatitis | RECRUITING | NCT07217015 |
| KT-621 | Other | Phase PHASE2 | Atopic Dermatitis | RECRUITING | NCT07217015 |
| Placebo | Other | Phase PHASE2 | Eosinophilic Asthma | RECRUITING | NCT07323654 |
| KT-621 | Other | Phase PHASE2 | Eosinophilic Asthma | RECRUITING | NCT07323654 |
| Placebo | Other | Phase PHASE2 | Atopic Dermatitis | RECRUITING | NCT07217015 |
| KT-621 | Other | Phase PHASE2 | Atopic Dermatitis | RECRUITING | NCT07217015 |
| Placebo | Other | Phase PHASE2 | Eosinophilic Asthma | RECRUITING | NCT07323654 |
| KT-621 | Other | Phase PHASE2 | Eosinophilic Asthma | RECRUITING | NCT07323654 |
| Placebo | Other | Phase PHASE2 | Eosinophilic Asthma | RECRUITING | NCT07323654 |
| KT-621 | Other | Phase PHASE2 | Eosinophilic Asthma | RECRUITING | NCT07323654 |
| Placebo | Other | Phase PHASE2 | Atopic Dermatitis | RECRUITING | NCT07217015 |
| KT-621 | Other | Phase PHASE2 | Atopic Dermatitis | RECRUITING | NCT07217015 |
| Placebo | Other | Phase PHASE2 | Eosinophilic Asthma | RECRUITING | NCT07323654 |
| KT-621 | Other | Phase PHASE2 | Eosinophilic Asthma | RECRUITING | NCT07323654 |
| Placebo | Other | Phase PHASE2 | Atopic Dermatitis | RECRUITING | NCT07217015 |
| KT-621 | Other | Phase PHASE2 | Atopic Dermatitis | RECRUITING | NCT07217015 |
| Placebo | Other | Phase PHASE2 | Eosinophilic Asthma | RECRUITING | NCT07323654 |
| KT-621 | Other | Phase PHASE2 | Eosinophilic Asthma | RECRUITING | NCT07323654 |
| Placebo | Other | Phase PHASE2 | Atopic Dermatitis | RECRUITING | NCT07217015 |
| KT-621 | Other | Phase PHASE2 | Atopic Dermatitis | RECRUITING | NCT07217015 |
| Placebo | Other | Phase PHASE2 | Eosinophilic Asthma | RECRUITING | NCT07323654 |
| KT-621 | Other | Phase PHASE2 | Eosinophilic Asthma | RECRUITING | NCT07323654 |
| Placebo | Other | Phase PHASE2 | Atopic Dermatitis | RECRUITING | NCT07217015 |
| KT-621 | Other | Phase PHASE2 | Atopic Dermatitis | RECRUITING | NCT07217015 |
| Placebo | Other | Phase PHASE2 | Eosinophilic Asthma | RECRUITING | NCT07323654 |
| KT-621 | Other | Phase PHASE2 | Eosinophilic Asthma | RECRUITING | NCT07323654 |
| Placebo | Other | Phase PHASE2 | Atopic Dermatitis | RECRUITING | NCT07217015 |
| KT-621 | Other | Phase PHASE2 | Atopic Dermatitis | RECRUITING | NCT07217015 |
| Placebo | Other | Phase PHASE2 | Eosinophilic Asthma | RECRUITING | NCT07323654 |
| KT-621 | Other | Phase PHASE2 | Eosinophilic Asthma | RECRUITING | NCT07323654 |
| Placebo | Other | Phase PHASE2 | Atopic Dermatitis | RECRUITING | NCT07217015 |
| KT-621 | Other | Phase PHASE2 | Atopic Dermatitis | RECRUITING | NCT07217015 |
| Placebo | Other | Phase PHASE2 | Eosinophilic Asthma | RECRUITING | NCT07323654 |
| KT-621 | Other | Phase PHASE2 | Eosinophilic Asthma | RECRUITING | NCT07323654 |
| Placebo | Other | Phase PHASE2 | Atopic Dermatitis | RECRUITING | NCT07217015 |
| KT-621 | Other | Phase PHASE2 | Atopic Dermatitis | RECRUITING | NCT07217015 |
| Placebo | Other | Phase PHASE2 | Eosinophilic Asthma | RECRUITING | NCT07323654 |
| KT-621 | Other | Phase PHASE2 | Eosinophilic Asthma | RECRUITING | NCT07323654 |
| Placebo | Other | Phase PHASE2 | Atopic Dermatitis | RECRUITING | NCT07217015 |
| KT-621 | Other | Phase PHASE2 | Atopic Dermatitis | RECRUITING | NCT07217015 |
| Placebo | Other | Phase PHASE2 | Atopic Dermatitis | RECRUITING | NCT07217015 |
| KT-621 | Other | Phase PHASE2 | Atopic Dermatitis | RECRUITING | NCT07217015 |
| KT-579 | DRUG | Phase PHASE1 | Healthy Participants | RECRUITING | NCT07412288 |
| Placebo | OTHER | Phase PHASE2 | Atopic Dermatitis | RECRUITING | NCT07217015 |
| KT-621 | DRUG | Phase PHASE2 | Atopic Dermatitis | RECRUITING | NCT07217015 |
| KT-253 | DRUG | Phase PHASE1 | Myeloid Malignancies | COMPLETED | NCT05775406 |
| KT-413 | DRUG | Phase PHASE1 | Non Hodgkin Lymphoma | COMPLETED | NCT05233033 |
| KT-333 | DRUG | Phase PHASE1 | Non Hodgkin Lymphoma (NHL) | COMPLETED | NCT05225584 |
| KT-474 | DRUG | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT04772885 |
| KT-474/Placebo | DRUG | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT04772885 |